KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.35.

  • Jazz Pharmaceuticals' Debt to Equity fell 758.38% to $1.35 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.35, marking a year-over-year decrease of 758.38%. This contributed to the annual value of $1.49 for FY2024, which is 239.2% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Debt to Equity is $1.35, which was down 758.38% from $1.45 recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Debt to Equity peaked at $2.09 during Q3 2022, and registered a low of $0.55 during Q1 2021.
  • Moreover, its 5-year median value for Debt to Equity was $1.54 (2024), whereas its average is $1.55.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Debt to Equity soared by 20165.47% in 2022 and then plummeted by 2148.57% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Debt to Equity stood at $1.53 in 2021, then grew by 21.58% to $1.86 in 2022, then dropped by 17.59% to $1.53 in 2023, then dropped by 2.39% to $1.49 in 2024, then fell by 9.25% to $1.35 in 2025.
  • Its Debt to Equity was $1.35 in Q3 2025, compared to $1.45 in Q2 2025 and $1.29 in Q1 2025.